Introduction：Basic information about Etidronate disodium CAS 7414-83-7, including its chemical name, molecular formula, synonyms, physicochemical properties, and safety information, etc.
Etidronate disodium Basic information
| Product Name: | Etidronate disodium |
| Synonyms: | Sodium etidronate;didronelr;disodium(1-hydroxyethylidene)diphosphonate;disodium1-hydroxyethylidenephosphonate;disodiumdihydrogen(1-hydroxyethylidene)diphosphonate;disodiumethanol-1,1-diphosphonate;disodiumethydronate;1-Hydroxyethylidone-1,1-diphosphonicaciddisodiumsalt |
| CAS: | 7414-83-7 |
| MF: | C2H9NaO7P2 |
| MW: | 230.02 |
| EINECS: | 231-025-7 |
| Product Categories: | Intermediates & Fine Chemicals;Pharmaceuticals;Other APIs;Phosphonate antiscalant |
| Mol File: | 7414-83-7.mol |
|
Etidronate disodium Chemical Properties
| Melting point | >300 °C |
| storage temp. | 15-25°C |
| solubility | H2O: 26 mg/mL |
| form | solid |
| color | white |
| Water Solubility | Soluble in water (26 mg/ml). |
| Merck | 14,3863 |
| Stability: | Hygroscopic |
| Cosmetics Ingredients Functions | CHELATING |
| Cosmetic Ingredient Review (CIR) | Etidronate disodium (7414-83-7) |
| InChI | InChI=1S/C2H8O7P2.Na.H/c1-2(3,10(4,5)6)11(7,8)9;;/h3H,1H3,(H2,4,5,6)(H2,7,8,9);; |
| InChIKey | MFKOTRZLMIUIGE-UHFFFAOYSA-N |
| SMILES | C(O)(C)(P(O)(O)=O)P(O)(O)=O.[NaH] |
| CAS DataBase Reference | 7414-83-7 |
| EPA Substance Registry System | Phosphonic acid, (1-hydroxyethylidene)bis-, disodium salt (7414-83-7) |
Safety Information
| Hazard Codes | Xn |
| Risk Statements | 22 |
| Safety Statements | 36/37/39 |
| WGK Germany | 1 |
| RTECS | SZ8562240 |
| TSCA | TSCA listed |
| HS Code | 29319090 |
| Storage Class | 11 - Combustible Solids |
| Hazard Classifications | Acute Tox. 4 Oral |
Etidronate disodium Usage And Synthesis
| Description | Agents in the first generation (e.g., etidronate disodium and tiludronate) that were dosed continuouslyproduced poorly mineralized bone, because there was no interval for appropriate bone mineralization tooccur. Subsequent studies that used a cyclic dosing schedule (400 mg/day for 2 weeks, followed by 2.5 monthsof calcium supplementation only) showed improvement in bone mineralization. Etidronate has beenapproved for treatment of Paget's disease of the bone but not for treatment of osteoporosis. Tiludronateis approximately 10-fold more potent than etidronate and, when given orally for 6 months (200, 400, or 800mg/day), increases BMD by 2%. No further bone loss was detected in patients 6 months after cessation oftherapy. |
| Chemical Properties | White Crystalline Solid |
| Originator | Etidron,Gentili,Italy,1977 |
| Uses | Used as a calcium regulator. A bisphosphonate bone resorptive inhibitor |
| Uses | Etidronate disodium is a bisphosphonate antiresorptive agent,it is used as a calcium regulator. |
| Uses | progestin |
| Uses | Sequestering and chelating agent; scale and corrosion inhibitor. |
| Definition | ChEBI: An organic sodium salt resulting from the replacement of two protons from etidronic acid (one from from each of the phosphonic acid groups) by sodium ions. |
| Manufacturing Process | Phosphorous acid was premixed with acetic acid to form a 50 wt % solution ofphosphorous acid dissolved in acetic acid. The acids were mixed on a molarbasis of 1.36:1, acetic acid to phosphorous acid, and this corresponded on amol percentage basis to 57.6% acetic acid and 42.4% phosphorous acid.Acetic anhydride was continuously metered into a stream of the phosphorousacid-acetic acid mixture to form the reaction solution. The acetic anhydridewas metered into the acid mixture at a mol ratio of 1.33 mols of aceticanhydride per mol of phosphorous acid. The metering rates were 18.5 lb/hr ofthe phosphorous acid/acetic acid premixed solution and 15.1 lb/hr aceticanhydride. The reaction solution was continuously passed through a heatexchanger where it was heated to 190°F then it was continuously fed into atwo stage back-mix reaction zone where due to the heat of reaction thetemperature rose to 275°F. The average residence in the reaction zone was 27min. The reaction zone consisted of two back-mix reactors each having acapacity of 7.5 pounds of the reaction solution. A stream of reaction solutionwas continuously with drawn from the second reactor and continuously mixedwith a stream of water which was being metered at a rate of 2 lb/hr. Thisamount of water corresponded to 18% excess over the theoretical amountnecessary to hydrolyze all of the acetyl-containing compounds in the reactionsolution to free acids. The hydrolyzed solution was continuously passedthrough a heat exchanger and cooled to room temperature after which thesolution was continuously passed to a crystallizer where, with agitation, theethane-1-hydroxy-1,1-diphosphonic acid crystallized. The slurry was thenfiltered and the crystals were recovered and dried. Analysis of the productshowed a conversion rate of phosphorous acid to ethane-1-hydroxy-1,1-diphosphonic acid of 86%. Sodium hydroxide may be used to give thedisodium salt. |
| Brand name | Didronel (Millot Laboratories, France);Didronel (Procter & Gamble). |
| Therapeutic Function | Bone calcium regulator |
| Biochem/physiol Actions | Etidronate helps to guard chronic ocular hypertension prompted retinal oxidative stress. It stimulates the development of retinal ganglion cells through insulin-like growth factor 1 (IGF-1) signaling pathway. It may possess neuroprotective effects in in vivo and in vitro rat model of glaucoma. Etidronate belongs to bisphosphonates. |
| Safety Profile | Poison by intravenous and subcutaneous routes. Moderately toxic by ingestion. An experimental teratogen. Other experimental reproductive effects. When heated to decomposition it emits toxic fumes of POx, and Na2O. |
| Veterinary Drugs and Treatments | Etidronate is a first generation bisphosphonate that may be usefulfor the treatment of severe hypercalcemia associated with neoplasticdisease. Its use in human medicine has been largely replacedwith newer, more potent bisphosphonates that can be dosed lessoften or have fewer adverse effects. Etidronate is also indicated inhumans for the treatment of Paget’s disease and heterotopic ossification(e.g., after total hip replacement). |
Etidronate disodium Preparation Products And Raw materials
| Preparation Products | water quality stabilizre DDF-1 |
